CN101422498A - Preparation method of ginseng capsule with anti-osteoporosis function using ginseng fibrous root as raw material - Google Patents
Preparation method of ginseng capsule with anti-osteoporosis function using ginseng fibrous root as raw material Download PDFInfo
- Publication number
- CN101422498A CN101422498A CNA2008101848309A CN200810184830A CN101422498A CN 101422498 A CN101422498 A CN 101422498A CN A2008101848309 A CNA2008101848309 A CN A2008101848309A CN 200810184830 A CN200810184830 A CN 200810184830A CN 101422498 A CN101422498 A CN 101422498A
- Authority
- CN
- China
- Prior art keywords
- ginseng
- osteoporosis
- ethanol
- leptoradix ginseng
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及用以人参须为原料制备具有抗骨质疏松功效的人参胶囊的方法，该生产方法包括人参须超微粉碎及乙醇提取得到的人参须有效成分部位群，以及药物制剂的制备：人参须有效成分部位群的提取主要是用贝利微粉机对人参须进行微粉化，乙醇提取包括用70％乙醇和40％乙醇两种不同比例的乙醇浸泡，加热回流提取，药物制剂的制备包括加适量淀粉，分装胶囊。研究表明用人参须有效成分部位群制备的药物制剂，对去卵巢大鼠导致的高转换型的骨质疏松有非常明显的预防和治疗作用，临床可用于老年性骨质疏松症的预防及治疗作用，特别是对绝经期后骨质疏松和对肾上腺糖皮质激素等药物造成的骨质疏松也有具有较好的预防及治疗作用。The present invention relates to a method for preparing ginseng capsules with anti-osteoporosis effect by using ginseng silk as a raw material. The production method includes the effective component parts of ginseng silk obtained by superfine grinding and ethanol extraction, and the preparation of pharmaceutical preparations: ginseng The extraction of the effective components of the ginseng is mainly to micronize the ginseng whiskers with a Bailey micronizer. The ethanol extraction includes soaking in two different proportions of ethanol, 70% ethanol and 40% ethanol, and heating and reflux extraction. The preparation of pharmaceutical preparations includes adding Appropriate amount of starch, divided into capsules. Studies have shown that the pharmaceutical preparation prepared from the effective components of ginseng has a very obvious preventive and therapeutic effect on the high-transition osteoporosis caused by ovariectomized rats, and it can be used clinically for the prevention and treatment of senile osteoporosis It also has a good preventive and therapeutic effect on postmenopausal osteoporosis and osteoporosis caused by drugs such as adrenal glucocorticoids.
Description
It is pharmaceutical preparation and the production method of health food-Yizhibao that feedstock production has anti-osteoporosis function that technical field the present invention relates to Leptoradix Ginseng.
The background technology postmenopausal osteoporosis is the commonly encountered diseases of women after menopause; be more common in after the menopause 15～20 years; this disease mainly causes owing to oestrogen deficiencies; it is a kind of high conversion type osteoporosis that is; promptly during this period of time, the postmenopausal women is because the osteoclast Showed Very Brisk causes bone resorption obviously to strengthen; the bone amount is lost in a large number; simultaneously, because the osteoblast of osteoclast mediation also activates in a large number, the skeletonization activity also strengthens; bone is synthetic also obviously to be increased; but because women's bone resorption is obviously greater than bone formation after menopause, bone loss is synthetic greater than bone; finally caused high conversion type osteoporosis; this is the health problem that the women all generally occurs after menopause, and serious osteoporosis can cause old people's spinal fracture, and the Hip Fracture incidence rate is increasing; complication is serious; normal long-term bed loses viability, and mortality rate is up to 15-30%; therefore preventing and treating osteoporosis and be not only modern medicine circle problem anxious to be solved, also is socialization's problem.From the All Around The World scope, the ratio that the women accounts in the whole population after menopause more than 60 years old constantly rises, and China has stepped into aging society at present, thereby pays close attention to body of women health after menopause, and improving the quality of living seems very important.
Osteoporosis has constitutional and Secondary cases two big classes, and primary osteoporosis is old and feeble concentrated reflection in essence, can be divided into postmenopausal osteoporosis (I type) and senile osteoporosis (II type).The former is more common in after the menopause 15～20 years because the women of oestrogen deficiencies is high conversion type osteoporosis; The latter is more common in the old people more than 70 years old, and the men and women all can fall ill, and mostly is low conversion type osteoporosis.The drug main of protect against osteoporosis will be divided into three types at present: a class is for suppressing the medicine of bone resorption, as estrogen, calcitonin, progestogen, diphosphonates etc.; Another kind of is to promote osteoplastic medicine, as fluoride, anabolic steroid hormone, Yi Pulafen etc.; The 3rd class is for the medicine of effect bone mineralising, as calcium preparation, vitamin D etc.The first kind is the main medicine of prevention, treatment postmenopausal osteoporosis, but there is serious adverse effects, its serious adverse reaction is to stimulate endometrial hyperplasia, increases the sickness rate of carcinoma of endometrium, and life-time service also can increase the sickness rate of breast carcinoma and cause metrorrhagia etc.Second class then is suitable for senile osteoporosis, but this class medicine also is in the starting stage of research and development, and good prospect is arranged, and on behalf of medicine fluoride proof, it can increase the bone amount, but can reduce bone mass and bring out secondary fracture.Clear and definite and the safety of the 3rd class curative effect of medication, but also have some untoward reaction.Therefore, seek curative effect certainly, the osteoporotic medicine of the control that has no side effect becomes a new research focus.
This project team is by a large amount of animal experiment studies and screening, the dry root of once having found Chinese medicine Araliaceae Radix Ginseng (Panaxginseng C.A.Mey) with and the extract Ginsengdiol histsaponin of dry root; The extract stem and leaf of Radix Ginseng total saponins of Stem and leaf of Radix Ginseng has the osteoporotic effect of tangible control, applied for national inventing patent in 2000, number of patent application is: ZL00104283.1, and this patent was obtained the authorization in 2004, and certificate of invention number is: No. 143882.Further our finder's Leptoradix Ginseng of research also has certain prevention of osteoporosis effect.With Leptoradix Ginseng is raw material, adopt Leptoradix Ginseng's effective part of saponin group of following method preparation that the removal ovary osteoporosis rat is had very significantly preventive effect: to carry out micronization with the Baily pulverizing mill, with 70% ethanol soaking at room temperature 24 hours, heating extraction 2 hours, filtering residue adds 40% soak with ethanol 24 hours again, heating extraction 2 hours, filter, get filtrate, merging filtrate 1,2 concentrate, to 100%.Leptoradix Ginseng's effective part of saponin group of this prepared indicates through zoopery, and the osteoporosis of senile high conversion type is had tangible preventive effect.
Summary of the invention is a kind of only being the Panax Capsule medicine production method with anti-osteoporosis function of composition of raw materials preparation for Chinese medicine Leptoradix Ginseng simply, this medicine production method mainly comprises Leptoradix Ginseng's effective ingredient part group that Leptoradix Ginseng's micronizing and ethanol extraction obtain, and these Leptoradix Ginseng's effective ingredient part group is prepared as the production method of Panax Capsule.The production method of Panax Capsule: get the Leptoradix Ginseng, pulverize, reuse Baily pulverizing mill carries out micronization, adds 8～15 times of 60～80% soak with ethanol 24～48 hours, and heating and refluxing extraction 2 times is filtered, and keeps filtrate.Filtering residue adds 40% soak with ethanol 24 hours again, and heating and refluxing extraction 1 time is filtered, and merging filtrate behind the recovery ethanol, is concentrated into extractum, adds appropriate amount of starch, is packed as capsule.Get final product.Can also be prepared into the pharmaceutical preparation or the health food of pill, tablet, granule, injection and any clinical acceptable osteoporosis by modern crafts with Leptoradix Ginseng's effective ingredient part group of this method preparation, be used for prevention and can treat postmenopausal osteoporosis and senile osteoporosis for clinical.
The specific embodiment:
1. the extracting method of Leptoradix Ginseng's osteoporosis effective ingredient part group: get the Leptoradix Ginseng, pulverize, carry out micronization with the Baily pulverizing mill, add 15 times of 70% soak with ethanol 24 hours, heating and refluxing extraction 2 times is filtered, reservation filtrate.Filtering residue adds 40% soak with ethanol 24 hours again, and heating and refluxing extraction 1 time is filtered, and keeps filtrate, merges 3 times filtrate, reclaims ethanol, is concentrated into 100%.
2. Leptoradix Ginseng's osteoporosis effective ingredient part group is prepared as the production method of Panax Capsule: get Leptoradix Ginseng 5.5kg, pulverize, reuse Baily pulverizing mill carries out micronization, adds 8% soak with ethanol 24 hours, and heating and refluxing extraction 2 times is filtered, and keeps filtrate.Filtering residue adds 40% soak with ethanol 24 hours again, and heating and refluxing extraction 1 time is filtered, and merging filtrate behind the recovery ethanol, is concentrated into extractum, adds appropriate amount of starch, is packed as the 1# capsule, makes 10000, and every contains raw medicinal herbs 0.55g; Every heavily about 0.29-0.31g of medicated powder.
3. press Leptoradix Ginseng's effective ingredient part group that method 1 is extracted, can also be prepared into the pharmaceutical preparation or the health food of pill, tablet, granule, injection and any clinical acceptable osteoporosis by modern crafts, supply clinical being used for to prevent to treat postmenopausal osteoporosis and senile osteoporosis.
Zhi Bei Leptoradix Ginseng's osteoporosis effective ingredient part group as stated above, its raw material Leptoradix Ginseng can use Radix Ginseng, Stem and leaf of Radix Ginseng, alabastrum of Radix Ginseng replaces.
Embodiment one:
1. the preparation of laboratory animal grouping administration and medicine
1.1 the preparation of medicine
1.1.1 Leptoradix Ginseng's superfine powder alcohol extract (Leptoradix Ginseng's osteoporosis effective ingredient part group)
Extracting method by the present invention's 1. Leptoradix Ginseng's osteoporosis effective ingredient part groups extracts: get the Leptoradix Ginseng, pulverize, carry out micronization with the Baily pulverizing mill, add 15 times of 70% soak with ethanol 24 hours, heating and refluxing extraction 2 times is filtered, and keeps filtrate.Filtering residue adds 40% soak with ethanol 24 hours again, and heating and refluxing extraction 1 time is filtered, and keeps filtrate, merges 3 times filtrate, reclaims ethanol, be concentrated into 100% (1g crude drug/ml) and 33% two kind of concentration.Detect middle dosage medicinal liquid (1g crude drug/ml) contain ginsenoside Rg1 6.63 ± 0.26mg/g crude drug, ginsenoside Rb1 32.62 ± 2.4mg/g crude drug, ginsenoside Re 40.85 ± 1.9mg/g crude drug through the HPLC method.
1.1.2 livial: be the tibolone sheet, Nanjing Ou Jianong produces company limited production, specification: 2.5mg/ sheet, lot number: LH-0502-10.
1.2 laboratory animal and raising condition
40 of the adult female unpregnancy SD rats of SPF level, body weight 271.67 ± 25.63g is provided by Guangdong Province's Experimental Animal Center, and Guangdong Province's laboratory animal certification of fitness numbering: word 2006A015 checks and affirm in Guangdong.The raising condition: raise indoor temperature and keep 24 ℃～28 ℃, humidity is 50%～60%, special chamber sub-cage rearing, two in every cage, the next day change bedding and padding, freely take the photograph water, ingest (standard feed that the court's animal center provides) weighs once weekly.
1.3 experimental design and grouping
All the other respectively organize rat with 3% pentobarbital sodium sterile solution 0.13ml100g except that sham operated rats during the removal ovary experiment
-1The BW intraperitoneal injection of anesthesia is sewed up after the aseptic condition hypogastric region excision bilateral ovaries, and the sham operated rats rat is only cut the flesh layer and enters the abdominal cavity and seek out and do not excise behind the ovary and the Hui Na abdominal cavity.Observe wound healing situation and conventional the raising after the operation, begin to do to irritate stomach prevention administration behind the observation 2d.32 rats are divided into 4 groups at random, are respectively every group each 8 of dosage group in sham operated rats, ovariectomized group, livial, the Leptoradix Ginseng's superfine powder alcohol extract, low dose group.2d behind the removal ovary, the positive control drug livial is pressed 0.25mgkg
-1Bwd
-1, Leptoradix Ginseng's superfine powder alcohol extract low dose group is that (100% is that 1g crude drug/ml) add the two volumes distilled water diluting becomes 33% medicinal liquid to middle dosage.Sham operated rats and ovariectomized group give the equivalent distilled water every day and irritate stomach, continuously 90d.
It is as follows that respectively organize the gastric infusion situation every day:
All rats kill preceding 13,14 days subcutaneous injection 25mg.kg
-1Quadracycline each once, in kill preceding 3,4 two days subcutaneous injection calcein 5mg.kg-1 each once, two fluorescent labelinies interval 10 days.Body weight of weighing weekly, the feeding of freely drinking water.After experiment finishes, with 3% pentobarbital sodium (1.5ml.kg
-1) right ventricle executions (to reduce erythrocyte in the bone marrow, get rid of interference, make osteocomma be easier to observation analysis) of thoroughly drawing blood behind the row intraperitoneal injection of anesthesia.Detect index: right side tibia epimere is made the undecalcified bone slice, the stage casing bone is made undecalcified bone abrasive disc, carries out osseous tissue morphometry parameter detecting; Get back bone calcium, phosphorus and the bone hydroxyproline content surveyed of right ulna hydrochloric acid digestion, get right femur and the 5th lumbar vertebra and measure its bone weight, bone density respectively, with this evaluation experimental rat bone composition, bone quantitative changeization; Taking by weighing weight in wet base calculating uterus, uterus index in addition changes substantially to observe the uterus.
2 assay methods
2.1 the mensuration of rat internal organs weight
Weight such as uterus and right femur (weight in wet base) adopts weight method, calculates uterus/weight ratio, femur/weight ratio.
2.2 the assay method of bone calcium, phosphorus and hydroxyproline content
After right ulna precision weighed, 80 ℃ of baking 72h were to constant weight, and precision is weighed and record once more.Subsequently every part of bone specimen is placed 10ml ampere bottle to add 6mol/L HCL 5ml, alcohol blast burner is burnt and is taken out filtration after bottleneck seals back 108 ℃ of baking box constant temperature digestion 24h.Filtrate is divided into two parts, and a with the content of 1:200 dilution back with elements such as ICP instrument mensuration Ca, P, establishing criteria product content and diluted sample multiple calculate the content of elements such as Ca, P again; Another part filtrate, femur dilutes with 1:10, behind accent pH value to 7.0～7.4, measures kit method with UV-752 type ultraviolet spectrophotometer working sample absorbance according to hydroxyproline (hyp), calculates hydroxyproline content in the bone according to formula.
2.3 osseous tissue morphometry method
Non-decalcification bone slice is made in tibia epimere dehydration plastic embedding, and thickness is 4 μ m and 9 μ m, and the transparent back of dimethylbenzene resin mounting is measured the dynamic and static morphology meterological of spongy bone parameter respectively with image analyzer.Static parameter comprises bone trabecula percentage rate (%Tb.Ar), bone trabecula thickness (Tb.Th), bone trabecula number (Tb.N), bone trabecula separating degree (Tb.Sp), the bone formation parameter comprises fluorescent perimeter percentage rate (%L.Pm) in the dynamic parameter, mineralising deposition (MAR), bone formation rate (BFR/BS), bone formation rate (BFR/BV), bone formation rate (BFR/BV); By dynamic parameter, can understand the amount and the speed of bone surface mineralising, and explain the reason that static parameter changes.Middle tibia dehydration plastic embedding, make non-decalcification bone abrasive disc, thickness is 40 μ m, the transparent back of dimethylbenzene resin mounting, measure cortical bone morphology meterological parameter such as cortical bone area (Ct.Ar) with image analyzer, cortical bone area percentage (%Ct.Ar), medullary cavity area percentage (%Ma.Ar).
2.4 the mensuration of bone density
Right femur of the U.S. DEXA of GE-Lunar company borne densitometers experiments of measuring isolated rat and the 5th lumbar spine bmd.
2.5 statistical analysis
Experimental data all uses x ± S to represent, adopts SPSS14.0 software.Relatively adopt one factor analysis of variance (ANOVA) between the group of normal distribution data, variance adopts the LSD check together; Heterogeneity of variance then adopts Tamhane ' s T2 check; After skewness distributes and then uses the Kruskal-Wallis rank test, further use Conover ' s t check difference between group more in twos again.
3. experimental result
3.1 Leptoradix Ginseng's superfine powder alcohol extract is to the influence of removal ovary rat uterus, femur weight
Leptoradix Ginseng's superfine powder alcohol extract sees Table 3.1 to the influence of removal ovary rat uterus, femur weight:
Table 3.1 Leptoradix Ginseng superfine powder alcohol extract is to the influence of removal ovary rat uterus, femur weight (x ± s)
| Group | Right femur weight/body weight (%) | Uterus weight/body weight (%) |
| Sham operated rats | 0.283±0.018 | 0.309±0.076 |
| Ovariectomized group | 0.223±0.018** | 0.054±0.019** |
| The livial group | 0.270±0.013ΔΔ | 0.234±0.064**ΔΔ |
| Dosage group among the Leptoradix Ginseng | 0.244±0.018Δ | 0.049±0.015 ** |
| Leptoradix Ginseng's low dose group | 0.245±0.018Δ | 0.053±0.016 ** |
*P＜0.05vs sham operated rats,
*P＜0.01vs sham operated rats, Δ P＜0.05vs ovariectomized group, Δ Δ P＜0.01vs ovariectomized group
By the result of table 3.1 as seen, compare with sham operated rats, ovariectomized group femur index significantly reduces (P＜0.01), compares each intervention group femur index with ovariectomized group and all improves (P＜0.05 or P＜0.01) in various degree; Compare with sham operated rats, the livial group obviously increases rat uterus weight outer (P＜0.01), each group of Leptoradix Ginseng's superfine powder alcohol extract all obviously descends (P＜0.01) with ovariectomized group rat uterus weight, compares with ovariectomized group, and Leptoradix Ginseng's superfine powder alcohol extract is respectively organized the uterus weight no significant difference.
3.2 the influence of Leptoradix Ginseng's superfine powder alcohol extract organic and calcium, phosphorus content to removal ovary rat ulna
Leptoradix Ginseng's superfine powder alcohol extract sees Table 3.2 to the organic matter (bone hyp/ is key heavy) of removal ovary rat ulna, the influence of inanimate matter (bone calcium/backbone is heavy):
Table 3.2 Leptoradix Ginseng superfine powder alcohol extract is to the influence of removal ovary rat ulna composition (x ± s)
| Key heavy (mg/g) bone calcium of group bone hyp//backbone heavy (mg/g) |
| Sham operated rats 17.1 ± 1.5 100.4 ± 8.3 |
| Ovariectomized group 14.1 ± 3.1 * 82.0±15.7 * |
| Livial group 18.0 ± 2.6 Δs 186.7 ± 56.9 Δ Δs |
| Dosage group 19.5 ± 4.1 Δs 100.1 ± 13.3 Δs among the Leptoradix Ginseng |
| Leptoradix Ginseng's low dose group 17.9 ± 1.5 Δs 91.3 ± 19.1 |
*P＜0.05vs sham operated rats,
*P＜0.01vs sham operated rats, Δ P＜0.05vs ovariectomized group, Δ Δ P＜0.01vs ovariectomized group
By table 3.2 as can be known, compare the hyp of ovariectomized group ulna, Ca 17.5%, 18.3% (P＜0.05) that descended respectively with sham operated rats; The prompting castrated rats has losing of bone calcium and ossein simultaneously.Compare with ovariectomized group, livial, Leptoradix Ginseng's superfine powder alcohol extract all can increase hyp, Ca (P＜0.01) respectively), illustrate that Leptoradix Ginseng's superfine powder alcohol extract can effectively prevent losing of castrated rats ulna hyp and Ca, effect and livial are suitable.
3.3 Leptoradix Ginseng's superfine powder alcohol extract is to the influence of removal ovary rat tibia epimere spongy bone morphometry static parameter
Leptoradix Ginseng's superfine powder alcohol extract sees Table 3.3 to the influence of static parameter %Tb.Ar (bone trabecula area percent), Tb.Th (bone trabecula thickness), Tb.N (bone trabecula quantity), Tb.Sp (bone trabecula separating degree) in the removal ovary rat tibia epimere bone histomorphometry:
Table 3.3 Leptoradix Ginseng superfine powder alcohol extract is to the influence of removal ovary rat spongy bone static parameter (x ± s)
| Group | ％Tb.Ar(％) | Tb.Th(μm) | Tb.N(#/mm) | Tb.Sp(μm) |
| Sham operated rats | 23.3±6.55 | 60.6±3.56 | 3.85±1.05 | 225.±113 |
| Ovariectomized group | 5.7±2.54 ** | 50.5±10.89 ** | 1.10±0.40 ** | 1020±526 * |
| The livial group | 11.3±4.75Δ | 53.8±6.65 | 2.07±0.71ΔΔ | 488±206Δ |
| Dosage group among the Leptoradix Ginseng | 16.6±1.76ΔΔ | 60.6±4.89Δ | 2.74±0.26ΔΔ | 3077±30.1 |
| Leptoradix Ginseng's low dose group | 12.6±3.51ΔΔ | 58.4±9.36 | 2.15±0.37ΔΔ | 421±97.5ΔΔ |
*P＜0.05vs sham operated rats,
*P＜0,01vs sham operated rats, Δ P＜0.05vs ovariectomized group, Δ Δ P＜0.01vs ovariectomized group
By table 3.3 as can be known: with sham operated rats relatively, the research of the bone morphometry of ovariectomized group observes that bone trabecula area percentage rate (%Tb.Ar) and Tb.Th (bone trabecula thickness), bone trabecula quantity (Tb.N) have reduced by 75.5%, 16.7% and 71.4% respectively in the static parameter of tibia epimere; Bone trabecula separating degree (Tb.Sp) has increased by 3.5 times (P＜0.01); And compare with ovariectomized group, livial, Leptoradix Ginseng's superfine powder alcohol extract can improve above-mentioned morphology parameter (P＜0.05 or P＜0.01) respectively in various degree, illustrate that Leptoradix Ginseng's superfine powder alcohol extract can effectively prevent removal ovary to the microstructural destruction of rat spongy bone.
3.4 Leptoradix Ginseng's superfine powder alcohol extract is to the influence of removal ovary rat tibia stage casing cortical bone bone static parameter
Leptoradix Ginseng's superfine powder alcohol extract sees Table 3.4 to the influence of removal ovary rat tibia stage casing cortical bone bone static parameter Ct.Ar (cortex area), %Ct.Ar (cortex area percentage rate), %Ma.Ar (bone marrow area percentage rate):
Table 3.4 Leptoradix Ginseng superfine powder alcohol extract is to the influence of removal ovary rat tibia stage casing cortical bone bone static parameter (x ± s)
| Group | Ct.Ar(mm 2) | ％Ct.Ar(％) | ％Ma.Ar(％) |
| Sham operated rats | 4.41±0.34 | 79.5±3.57 | 20.5±3.57 |
| Ovariectomized group | 4.26±0.50 | 76.3±2.19 * | 23.7±2.19 * |
| The livial group | 4.23±0.31 | 76.4±2.75 | 23.6±2.76 |
| Dosage group among the Leptoradix Ginseng | 4.84±0.45Δ | 78.5±2.01 | 21.5±2.01 |
| Leptoradix Ginseng's low dose group | 4.79±0.67 | 79.1±1.54ΔΔ | 20.9±1.53ΔΔ |
*P＜0.05vs sham operated rats,
*P＜0.01vs sham operated rats, Δ P＜0.05vs ovariectomized group, Δ Δ P＜0.01vs ovariectomized group
By table 3.4 as can be known, compare with sham operated rats, the %Ma.Ar increase of ovariectomized group rat shows that medullary cavity enlarges, and %Ct.Ar reduces prompting cortical bone area minimizing (P＜0.05); And Leptoradix Ginseng's superfine powder alcohol extract can make the Ct.Ar of rat obviously increase (P＜0.05).Illustrate that Leptoradix Ginseng's superfine powder alcohol extract has certain effect to the cortical bone formation of removal ovary rat stage casing bone.
3.5 Leptoradix Ginseng's superfine powder alcohol extract is to the influence of removal ovary rat bone density
Leptoradix Ginseng's superfine powder alcohol extract sees Table 3.5 to the influence of right femur of removal ovary rat and the 5th lumbar spine bmd:
Table 3.5 Leptoradix Ginseng superfine powder alcohol extract is to the influence of right femur of removal ovary rat and the 5th lumbar spine bmd (x ± s)
*P＜0.05vs sham operated rats,
*P＜0.01vs sham operated rats, Δ P＜0.05vs ovariectomized group, Δ Δ P＜0.01vs ovariectomized group
By table 3.5 as can be known, compare ovariectomized group rat femur and the 5th lumbar spine bmd significantly descend (P＜0.01, P＜0.05) with sham operated rats; Livial, Leptoradix Ginseng's superfine powder alcohol extract all can make the castrated rats bone density increase (P＜0.01 or P＜0.05), and wherein Leptoradix Ginseng's superfine powder alcohol extract is more obvious than livial to the influence of lumbar spine bmd.
Above result shows that the osteoporosis that Leptoradix Ginseng's superfine powder alcohol extract causes removal ovary has tangible prevention and therapeutical effect.Can be used for prevention and can treat postmenopausal osteoporosis and senile osteoporosis.
Claims (3)
1, a kind of is the production method of the Panax Capsule with anti-osteoporosis function of feedstock production with Leptoradix Ginseng, it is characterized in that this production method comprises Leptoradix Ginseng's effective ingredient part group that Leptoradix Ginseng's micronizing and ethanol extraction obtain, and the preparation of pharmaceutical preparation: the extraction of Leptoradix Ginseng's effective ingredient part group mainly is with the Baily pulverizing mill Leptoradix Ginseng to be carried out micronization, ethanol extraction comprises the soak with ethanol with 70% ethanol and two kinds of different proportions of 40% ethanol, heating and refluxing extraction, the preparation of pharmaceutical preparation comprises and adds appropriate amount of starch, divides encapsulated; Its concrete production method is as follows: get Leptoradix Ginseng 5.5kg, pulverize, reuse Baily pulverizing mill carries out micronization, adds 8% soak with ethanol 24 hours, and heating and refluxing extraction 2 times is filtered, and keeps filtrate.Filtering residue adds 40% soak with ethanol 24 hours again, and heating and refluxing extraction 1 time is filtered, merging filtrate, reclaim ethanol after, be concentrated into extractum, add appropriate amount of starch, divide encapsulated, promptly.
2, as claimed in claim 1 a kind of be the production method of the Panax Capsule with anti-osteoporosis function of feedstock production with Leptoradix Ginseng, also can be prepared into the pharmaceutical preparation or the health food of pill, tablet, granule, injection and any clinical acceptable osteoporosis by modern crafts, supply clinical being used for to prevent to treat postmenopausal osteoporosis and senile osteoporosis.
3, as claimed in claim 1 a kind of be the production method of the Panax Capsule with anti-osteoporosis function of feedstock production with Leptoradix Ginseng, its raw material Leptoradix Ginseng can use Radix Ginseng, Stem and leaf of Radix Ginseng, alabastrum of Radix Ginseng replaces.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101848309A CN101422498A (en) | 2008-11-27 | 2008-11-27 | Preparation method of ginseng capsule with anti-osteoporosis function using ginseng fibrous root as raw material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101848309A CN101422498A (en) | 2008-11-27 | 2008-11-27 | Preparation method of ginseng capsule with anti-osteoporosis function using ginseng fibrous root as raw material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101422498A true CN101422498A (en) | 2009-05-06 |
Family
ID=40613527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101848309A Pending CN101422498A (en) | 2008-11-27 | 2008-11-27 | Preparation method of ginseng capsule with anti-osteoporosis function using ginseng fibrous root as raw material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101422498A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102366431A (en) * | 2011-10-30 | 2012-03-07 | 广东医学院 | Application of ginseng flower in preparing medicinal preparation for controlling osteoporosis |
| CN119326868A (en) * | 2024-12-20 | 2025-01-21 | 长春中医药大学 | A refined component of ginseng and antlers, and its preparation method and application |
| CN119326868B (en) * | 2024-12-20 | 2025-04-11 | 长春中医药大学 | A refined component of ginseng and antlers, and its preparation method and application |
-
2008
- 2008-11-27 CN CNA2008101848309A patent/CN101422498A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102366431A (en) * | 2011-10-30 | 2012-03-07 | 广东医学院 | Application of ginseng flower in preparing medicinal preparation for controlling osteoporosis |
| CN119326868A (en) * | 2024-12-20 | 2025-01-21 | 长春中医药大学 | A refined component of ginseng and antlers, and its preparation method and application |
| CN119326868B (en) * | 2024-12-20 | 2025-04-11 | 长春中医药大学 | A refined component of ginseng and antlers, and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104306959A (en) | Medicine composition for treating osteoporosis and preparation method thereof | |
| CN102397328B (en) | Traditional Chinese medicine composition used for treating fractures, preparation method thereof, and application thereof | |
| CN102120020B (en) | A pharmaceutical composition for treating cyclomastopathy and hysteromyoma, and its preparation method | |
| CN103239590A (en) | Traditional Chinese medicine composition as well as preparation and application thereof | |
| CN102266415B (en) | Application of compound traditional Chinese medicine in prevention and treatment of osteoporosis disease | |
| CN101380359B (en) | Bone-building capsules and preparation method thereof | |
| CN101138597B (en) | A traditional Chinese medicine preparation for preventing and treating osteoporosis and its preparation method | |
| CN115844941B (en) | Eucommia ulmoides extract composition and application thereof in preparation of anti-osteoporosis drugs | |
| CN101461894A (en) | A pharmaceutical composition for treating female climacteric syndrome and delaying aging | |
| CN104257762B (en) | A kind of pharmaceutical composition and prevention thereof and the osteoporotic purposes for the treatment of | |
| CN106236799A (en) | The application in preparation treatment perimenopausal syndrome medicine of the Fructus Cnidii total flavones | |
| CN101422498A (en) | Preparation method of ginseng capsule with anti-osteoporosis function using ginseng fibrous root as raw material | |
| CN101618133B (en) | Application of yang-reinforcing kidney-protecting medicine in preparing medicine preventing and treating osteoporosis | |
| CN100594918C (en) | Compound Chinese medicinal oral preparation for treating osteoporosis and preparation method thererof | |
| CN102048890A (en) | Traditional Chinese medicine composition with galactagogue effect and preparation method thereof | |
| CN102048841A (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN103479783A (en) | Chinese medicine composite for curing climacteric melancholia and application thereof | |
| WO2021179482A1 (en) | Traditional chinese medicine compound composition having effect of promoting bone health as well as preparation method therefor and application thereof | |
| CN102600418A (en) | Medicinal composition for treating female climacteric syndrome, and preparation method thereof | |
| CN107496503A (en) | A kind of capsule preparations for being used to increase bone density | |
| CN102366493A (en) | Traditional Chinese medicine compound extract for treating postmenopausal osteoporosis and preparation method thereof | |
| CN106138955A (en) | The application in exhausted premenstrual syndrome medicine is treated in preparation of the Fructus Alpiniae Oxyphyllae total flavones | |
| WO2021160104A1 (en) | Folium apocyni veneti extract, and preparation method therefor and use thereof | |
| CN115192654B (en) | New medical application of radix angelicae sinensis blood-activating preparation | |
| CN102961518B (en) | Application for ginseng-rhizoma curculiginis combined medicine for preparation for medicine used for treating osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090506 |